Search This Blog

Thursday, February 21, 2019

Piper: Japanese national reimbursement should be ‘solid win’ for LivaNova

After LivaNova announced that it has obtained Japanese national reimbursement for its Perceval sutureless aortic valve, Piper Jaffray analyst Matt O’Brien said he believes the announcement should be a “solid win” for the company that boosts growth in 2019 and 2020. O’Brien keeps an Overweight rating on LivaNova shares ahead of the company’s earnings call next week.
https://thefly.com/landingPageNews.php?id=2867945

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.